Philip Morris International (PM) has disclosed a new risk, in the Corporate Activity and Growth category.
Philip Morris International faces significant business risk following its acquisitions of Swedish Match and Vectura Fertin Pharma. Despite the formation of a new Wellness and Healthcare business, there is no certainty that the expected synergies and benefits will materialize fully or within the anticipated timeframe. The success hinges on Swedish Match’s competitive market performance and Vectura Fertin Pharma’s R&D outcomes, including regulatory approvals and commercialization of new products. Additionally, the company’s traditional combustible product line could impede the growth and acceptance of its new health-oriented offerings, potentially undermining efforts to establish a sustainable product ecosystem in the wellness and healthcare sectors.
Overall, Wall Street has a Moderate Buy consensus rating on PM stock based on 5 Buys and 2 Holds.
To learn more about Philip Morris International’s risk factors, click here.
